Cellular Origins

United Kingdom - Royston, Hertfordshire

• 17/12/2025
• Series A
• $40,000,000

Cellular Origins, a TTP company, is focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies.

Created to provide therapeutic developers access to the equipment they want, at the capacity they need, Cellular Origins’ proprietary technology addresses the challenges associated with manufacturing at scale, with an elegant solution for automated sterile fluidic interconnection that reduces cost and labour, eliminating human error, and increasing efficiency.

Related People

Edwin StoneFounder

United Kingdom - Cambridge, England

Cell and gene therapies have shown the ability to cure some of the most terrible diseases. I am passionate about finding ways to get these treatments to more patients by revolutionizing how we manufacture them.

For nearly 20 years, I have been fortunate to work with some of the world's most innovative companies to help bring new life science products to market. The last 8 years I have dedicated to cell and gene therapy manufacturing, spanning from commercial strategy through technology development and onto production.

Following a PhD in robotic vehicles at Cambridge University, I worked on some of the earliest EMA approved cell therapies and since then I have been involved in the development of over 10 novel cell therapy automation platforms.

LinkedIn https://www.linkedin.com/in/edwin-stone/